- Split View
-
Views
-
Cite
Cite
Tomoko Ozawa, Sergei M. Gryaznov, Lily J. Hu, Krisztina Pongracz, Raquel A. Santos, Andrew W. Bollen, Kathleen R. Lamborn, Dennis F. Deen, Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts, Neuro-Oncology, Volume 6, Issue 3, July 2004, Pages 218–226, https://doi.org/10.1215/S1152851704000055
- Share Icon Share
Abstract
Telomerase is a ribonucleoprotein complex that elongates telomeric DNA and appears to play an important role in cellular immortalization of cancers. Because telomerase is expressed in the vast majority of malignant gliomas but not in normal brain tissues, it is a logical target for glioma-specific therapy. The telomerase inhibitor GRN163, a 13-mer oligonucleotide N3′→P5′ thio-phosphoramidate (Geron Corporation, Menlo Park, Calif.), is complementary to the template region of the human telomerase RNA subunit hTR. When athymic mice bearing U-251 MG human brain tumor xenografts in their flanks were treated intratumorally with GRN163, a significant growth delay in tumor size was observed (P < 0.01 in all groups) as compared to the tumor size in mice receiving a mismatched oligonucleotide or the carrier alone. We also investigated biodistribution of the drug in vivo in an intracerebral rat brain-tumor model. Fluorescein-labeled GRN163 was loaded into an osmotic minipump and infused directly into U-251 MG brain tumors over 7 days. Examination of the brains revealed that GRN163 was present in tumor cells at all time points studied. When GRN163 was infused into intracerebral U-251 MG tumors shortly after their implantation, it prevented their establishment and growth. Lastly, when rats with larger intracerebral tumors were treated with the inhibitor, GRN163 increased animal survival times. Our results demonstrate that the antitelomerase agent GRN163 inhibits growth of glioblastoma in vivo, exhibits favorable intracerebral tumor uptake properties, and prevents the growth of intracerebral tumors. These findings support further development of this compound as a potential anticancer agent.
References
Burger, P.C., Scheithauer, B.W., and Vogel, F.S. (
Chong, E.Y., Lam, P.Y., Poon, W.S., and Ng, H.K. (
Counter, C.C., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W., Harley, C.B., and Bacchetti, S. (
Greider, C.W., and Blackburn, E.H. (
Gryaznov, S.M., and Letsinger, R.L. (
Gryaznov, S.M., Pongracz, K., Matray, T., Schultz R., Pruzan R., Aimi, J., Chin, A., Harley, C., Shea-Herbert, B., Shay, J., Oshima, Y., Asai, A., and Yamashita, Y. (
Hakin-Smith, V., Jellinek, D.A., Levy, D., Carroll, T., Teo, M., Timperley, W.R., McKay, M.J., Reddel, R.R., and Royds, J.A. (
Herbert, B.-S., Pongracz, K., Shay, J.W., and Gryaznov, S.M. (
Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M.A., and Shay, J.W. (
Hollander, M., and Wolfe, D.A. (
Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, P.L., Coviello, G.M., Wright, W.E., Weinrich, S.L., and Shay, J.W. (
Kondo, S., Kondo, Y., Li, G., Silverman, R.H., and Cowell J.K. (
Langford, L.A., Piatyszek, M.A., Xu, R., Schold, S.C., Jr., and Shay, J.W. (
Le, S., Zhu, J.J., Anthony, D.C., Greider, C.W., and Black, P.M. (
Levin, V.A., Silver, P., Hannigan, J., Wara, W.M., Gutin, P.H., Davis, R.L., and Wilson, C.B. (
Lin, Y., Miyamoto, H., Fujinami, K., Uemura, H., Hosaka, M., Iwasaki, Y., and Kubota, Y. (
Mao, L., El-Naggar, A.K., Fan, Y.H., Lee, J.S., Lippman, S.M., Kayser, S., Lotan, R., and Hong, W.K. (
Miller, P.J., Hassanein, R.S., Giri, P.G., Kimler, B.F., O'Boynick, P., and Evans, R.G. (
Mori, K., Tanaka, R., Onda, K., Tsumanuma, I., and Yoshimura, J. (
Mukai, S., Kondo, Y., Koga, S., Komata, T., Barna, B.P., and Kondo, S. (
Ozawa, T., Wang, J., Hu, L.J., Lamborn, K.R., Bollen, A.W., and Deen, D.F. (
Ozawa, T., Wang, J., Hu, L.J., Bollen, A.W., Lamborn K.R., and Deen, D.F. (
Pongracz, K., and Gryaznov, S.M. (
Recht, L., Fram, R.J., Strauss, G., Fitzgerald, T.J., Liepman, M., Lew, R., Kadish, S., Sherman, D., Wilson, J., Greenberger, J., Egan, P., and Silver, D. (
Sano, T., Asai, A., Mishima, K., Fujimaki, T., and Kirino, T. (
Shibamoto, Y., Yamashita, J., Takahashi, M., Yamasaki, T., Kikuchi, H., and Abe, M. (
Sommerfeld, H.J., Meeker, A.K., Piatyszek, M.A., Bova, G.S., Shay, J.W., and Coffey, D.S. (
Sugino, T., Yoshida, K., Bolodeoku, J., Tahara, H., Buley, I., Manek, S., Wells, C., Goodison, S., Ide, T., Suzuki, T., Tahara, E., and Tarin, D. (
Author notes
Brain Tumor Research Center of the Department of Neurological Surgery (T.O., L.J.H., R.A.S., K.R.L., D.F.D.) andDepartment of Pathology (A.W.B.), University of California San Francisco, San Francisco, CA 94143-0520; andGeron Corporation, Menlo Park, CA 94025 (S.M.G., K.P.); USA